Entacapone Orion 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
WS/2096 
This was an application for a variation following a 
21/10/2021 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IG/1277 
B.II.b.2.c.1 - Change to importer, batch release 
08/10/2020 
29/09/2021 
Annex II and PL 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
WS/1735/G 
This was an application for a group of variations 
12/03/2020 
n/a 
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008. 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
non-significant specification parameter (e.g. deletion 
of an obsolete parameter) 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
PSUSA/1223/
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
201901 
entacapone 
N/0017 
Minor change in labelling or package leaflet not 
30/08/2019 
29/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/0982/G 
This was an application for a group of variations. 
26/10/2018 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
IG/0888 
A.7 - Administrative change - Deletion of 
29/01/2018 
n/a 
manufacturing sites 
WS/1064 
This was an application for a variation following a 
15/12/2016 
28/11/2017 
SmPC, Annex 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
and PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/1223/
Periodic Safety Update EU Single assessment - 
02/09/2016 
n/a 
PRAC Recommendation - maintenance 
201601 
entacapone 
R/0011 
Renewal of the marketing authorisation. 
25/02/2016 
08/04/2016 
Based on the review of data on quality, safety and efficacy, 
N/0010 
Minor change in labelling or package leaflet not 
29/09/2015 
25/01/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
the CHMP considered that the benefit-risk balance of 
Entacapone Orion in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0546 
C.I.8.a - Introduction of or changes to a summary of 
27/04/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the PSMF 
location 
WS/0665 
This was an application for a variation following a 
22/01/2015 
25/01/2016 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
To update the Product Information as follows: 
- to include ADR statement 
- to update the PI to QRD template version 9 
- to include an explanation to the PL of the pictogram 
which is currently only displayed on the carton (all 
products except Comtan) 
- to correct the local contact information for Malta in 
Stalevo PL 
- to correct the local contact information for Latvia in 
all PLs except for Comtan and Entacapone Orion 
- to correct the local contact information for Germany 
in Comtess and Levodopa/Carbidopa/Entacapone 
Orion 
- for Comtan only: to add 'Magnesium stearate' to the 
list of excipients for the film-coating in the SmPC and 
PL. Tablet core and Film-coating both contain 
magnesium stearate 
- to correct linguistic amendments in Annexes 
- to amend a mistake in the Annex A (only for 
Comtan). 
C.I.z - Changes (Safety/Efficacy) of Human and 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
Veterinary Medicinal Products - Other variation 
IG/0433/G 
This was an application for a group of variations. 
08/05/2014 
n/a 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
N/0006 
Minor change in labelling or package leaflet not 
19/08/2013 
25/01/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/0331 
This was an application for a variation following a 
13/12/2012 
14/01/2013 
SmPC, Annex 
Based on a recent review of the available post-marketing 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
data in relation to the risk of development of impulse control 
and PL 
disorders when using medicinal products containing 
Update of SmPC sections 4.4 and 4.8 in order to 
update the safety information by implementing class 
labelling for the risk of impulse control disorders. 
C.I.3.z - Implementation of change(s) requested 
following the assessment of an USR, class labelling, a 
PSUR, RMP, FUM/SO, data submitted under A 45/46, 
or amendments to reflect a Core SPC - Other variation 
levodopa, dopamine agonists and/or 
catechol-O-methyltransferase (COMT) inhibitors, the 
CHMP/PhVWP requested a class labelling to update and 
harmonise the product information of all products concerned. 
In response to this request, the product information was 
updated to reflect behavioural symptoms related to impulse 
control disorders including compulsive spending or buying, 
binge eating and compulsive eating. It was clarified that this 
adverse reaction can occur irrespective of the indication and 
at normal doses. Furthermore, regular monitoring of patients 
and a careful review of treatment, if symptoms occur, is 
recommended. The Package Leaflet was updated in 
accordance and advice for the patient’s family and carers was 
provided. 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0004 
The Marketing Authorisation Holder (MAH) took the 
11/07/2012 
14/01/2013 
PL 
opportunity to update details of local representatives 
in Annex IIIB. Furthermore, incorrect package sizes 
were corrected in section 6 of the Portugese package 
leaflet. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
N/0003 
Minor change in labelling or package leaflet not 
20/03/2012 
14/01/2013 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/0199 
This was an application for a variation following a 
19/01/2012 
19/01/2012 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.III.2.a.1 - Change of specification('s) of a former 
non Pharmacopoeial substance to comply with the Ph. 
Eur. or with a national pharmacopoeia of a Member 
State - AS 
IG/0110 
C.I.9.i - Changes to an existing pharmacovigilance 
04/10/2011 
n/a 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same MAH 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
